How Could In Vitro Antiviral Activity Be Applied to Optimize the Dosing Regimens of Candidates for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)?

Jia, Ranran; Wang, Hongyun

Jia, Ranran; Wang, Hongyun.

Afiliación

Jia R; Clinical Pharmacology Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Damucang Hutong, Xicheng District, Beijing, China.
Wang H; Clinical Pharmacology Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Damucang Hutong, Xicheng District, Beijing, China.

Clin Infect Dis ; 73(2): 352-353, 2021 07 15.

Article en En | MEDLINE | ID: mdl-33244589

Asunto(s)

Antivirales; COVID-19; Animales; Antivirales/uso terapéutico; Chlorocebus aethiops; Humanos; SARS-CoV-2; Células Vero

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antivirales / COVID-19 Límite: Animals / Humans Idioma: En Revista: Clin Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2021 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google